A metisergide no tratamento da epilepsia temporal Methysergide in the treatment of temporal lobe epilepsy

• Main Author: Jorge Armbrust-Figueiredo
• Format: Article
• Language: English
• Published: Academia Brasileira de Neurologia (ABNEURO) 1967-09-01
• Series: Arquivos de Neuro-Psiquiatria
• Online Access: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0004-282X1967000300007
• ISSN: 0004-282X; 1678-4227

A metisergide (butanolamida do ácido 1-metil-lisérgico) foi empregada experimentalmente em 78 pacientes com epilepsia psicomotora e com alterações focais (ondas "sharp") de projeção em um dos lobos temporais, no EEG. Foram usadas doses diárias de 2 a 6 mg, associadas a 0,1 g de fenobarbital. Dos 78 pacientes, 59 responderam de maneira favorável ao tratamento, sendo que 47 deixaram de sofrer crises e 12 apresentaram diminuição acentuada da freqüência e intensidade das crises. As manifestações psíquicas também melhoraram com o tratamento, ao contrário do que geralmente acontece com outras drogas. As alterações eletrencefalográficas desapareceram ou melhoraram em 64% dos pacientes. Reações secundárias ocorreram em 39 dos pacientes, na fase inicial do tratamento, e foram de curta duração, desaparecendo espontâneamente.<br>Methysergide (1-methyl-lysergic acid butanolamide) was used experimentally in 78 patients with psychomotor epilepsy and with focal abnormal activity (sharp waves) in one of the temporal lobes, in the EEG. The usual dosage of methysergide was 2 to 6 mg daily (only 36 patients received more than 2 mg daily) and every patient received fenobarbital 0.1 g daily also. Out of the 78 patients, 59 responded well to the treatment; 47 were free of seizures and in 12 there was decrease in frequency and severity of seizures. Psychic symptoms also decreased with the use of methysergide. The EEG was improved in 27 per cent of patients and became normal in 37 per cent, after twelve months of treatment. Slight side effects were reported by 39 pacients but they disappeared in a few days.